The competition’s heating up over a $35 billion market to treat NASH, a ‘silent disease’ millions are living with. But some of the early results don’t look promising.
|02/12/2019||Posted by BusinessMediaguide.Com under General World News||
- NASH, short for nonalcoholic steatohepatitis, is a type of liver disease in which liver fat builds up in people.
- It affects an estimated 16 million Americans, but many don’t know it until it leads to more serious problems like liver failure and cirrhosis.
- Drugmakers are looking at different ways to treat the condition — both early and later as the disease progresses. Some are conducting research to better understand the genetics and other factors associated with NASH.
- On Monday, Gilead said that its first late-stage NASH trial for its drug selonsertib had failed. Analysts said the company’s appetite to tackle read more >>>